Meeting
2014 ASCO Annual Meeting
Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).
Authors
Antoinette R. Tan
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Antoinette R. Tan , Serena Tsan-Lai Wong , Robert D. Warren , Jennifer Eng-Wong , Minetta C. Liu , Amelia Bruce Zelnak , Yong Lin , Weichung Shih , Shridar Ganesan , Generosa Grana , Claudine Isaacs , Deborah Toppmeyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT00634634
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 531)
DOI
10.1200/jco.2014.32.15_suppl.531
Abstract #
531
Poster Bd #
21
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.
First Author: Frederik Marme
Poster
2013 ASCO Annual Meeting
BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+ HER2- metastatic breast cancer.
First Author: William John Gradishar
Poster
2023 ASCO Annual Meeting
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).
First Author: Masatoshi Kudo
Poster
2023 ASCO Annual Meeting
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup.
First Author: Arndt Vogel